Exhibitor Tutorial

Real-Time Cell Health Assays Deliver Better Data with Less Effort

Monday, February 5
12:30 PM - 1:15 PM
Location: Room 10

All compounds have an acute cytotoxic potential that is linked to dose and exposure. Defining the magnitude and scope of this potential has been a challenge for traditional endpoint cell health methods in terms of efficiency and resource utilization. Promega has developed a suite of homogeneous, add-mix-measure assays that report changes in cell health as they occur. The assays can be employed on the BMG LABTECH CLARIOstar® equipped with an atmospheric control unit (ACU), in a true “walk-away” workflow that allows continuous data collection for up to 72hr of exposure. This tutorial will detail our efforts to characterize the dose- and time-dependent, on- and off-target cytotoxicity associated with an antibody drug conjugate and a proteasome inhibitor. Particular attention will be devoted to the relative merits of kinetic formats versus endpoint methods with respect to data quality and degree of experimental confidence.

This tutorial is intended for innovative scientists engaged in assay development, screening programs or early drug discovery.

Carl Peters

Senior Applications Scientist
BMG Labtech

Dr. Carl Peters is a microplate reader Senior Application Scientist with BMG LABTECH. He obtained a PhD in Cell and Molecular Biology from Northwestern University while studying Protein Kinase C signaling. He also has a B.S. in Biology from Hastings College. Prior to BMG LABTECH, he was an adjunct or assistant professor of Biology, Biochemistry and Molecular Biology at several different universities.

Presentation(s):

Send Email for Carl Peters

Terry Riss

Global Strategic Manager, Cell Health
Promega Corporation

Dr. Riss received a PhD in Cell Biology from the University of Illinois in 1978 in the field of mammary gland biology. He did postdoctoral work at the University of Texas Medical School in Houston purifying growth factors involved with breast cancer and developing serum-free media formulations to implement bioassays. Dr. Riss moved to the Biotechnology division of Schering Plough in 1988 to develop interleukin/cytokine bioassays to support investigational new drug filings. Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and has held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Global Strategic Marketing Manager, Cell Health involved in outreach educational training activities. Dr. Riss has participated in several NIH study sections reviewing HTS grants and is co-editor of the cell culture assays section of the Assay Guidance Manual hosted by NIH.

Presentation(s):

Send Email for Terry Riss


Assets

Real-Time Cell Health Assays Deliver Better Data with Less Effort



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Real-Time Cell Health Assays Deliver Better Data with Less Effort